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Abstract: In massive pulmonary embolism (PE), fibrinolytic therapy is a potential lifesaving treatment; therefore, if other
treatments are not available, the physicians encounter this question: can we accept the risk of complications
from fibrinolytic therapy, especially intracranial hemorrhage, in the presence of absolute contraindication, in
order to save the patient’s life? Here, we describe three cases of massive PE with absolute contraindication for
fibrinolytic therapy who presented to emergency department following dyspnea. Since, surgical or catheter
embolectomy were not available and patients were very high risk for transferring to another hospital, systemic
fibrinolytic was administered. The patients improved clinically and were discharged from hospital. It seems
that, if no other acceptable treatments are available, physicians could consider fibrinolytic therapy, even at the
presence of contraindication, to save the patient’s life.
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1. Introduction
Pulmonary embolism (PE) is the most common cause of pre-
ventable death in hospitalized patients. Massive PE accounts
for 5-10 % of PE cases and has a high mortality rate (up to
30 – 50%) (1, 2). Massive PE affects at least half of the pul-
monary vessels, leading to right ventricular (RV) dilation and
dysfunction, and low blood pressure that is resistance to fluid
therapy and inotrope administration (3, 4). Hallmarks of
massive PE are hypotension, dyspnea and cyanosis. Hemo-
dynamic collapse and syncope can be the initial presentation
and the most common cause of early death in first days (5-
7). Fibrinolytic therapy can be lifesaving and prevent com-
plications such as RV failure, cardiogenic shock, and multi
system organ failure. Contraindication exclusion is neces-
sary for minimize bleeding risk. Although the risk of bleeding
due to fibrinolytic therapy is low (10 %) (8-10), fibrinolytic ad-
ministration in patients with absolute contraindication and
no other available acceptable treatment is a challenging de-
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cision. Here we describe three cases of massive PE with ab-
solute contraindication for fibrinolytic therapy who were dis-
charged from hospital after successful treatment.
2. Case presentation:
Case 1
A 54-year-old man presented to our emergency department
because of sudden onset of dyspnea and an episode of loss
of consciousness for 2 minutes. He had a history of is-
chemic cerebrovascular accident (CVA) 20 days before and
was bedridden after that. Initial physical examination re-
vealed blood pressure (BP): 75/45 mmHg, heart rate (HR)
160/minute, respiratory rate (RR) 35/minute, O2 saturation
60% in room air that increased to 90% when using nasal
O2. He was afebrile without any signs and symptoms of pul-
monary edema but jugular vein pressure (JVP) was elevated.
No edema was detected in lower limbs and color Doppler ul-
trasonography didn’t show any evidence of thrombus. A bed-
side electrocardiogram showed sinus tachycardia with nega-
tive T wave in V1 - V3.
The result of arterial blood gas (ABG) analysis was as follows:
pH=7.19, PCO2=30, Base excess (BE) =-15. Trans-thoracic
echocardiography (Figure 1.1) revealed severe RV dilation
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Figure1. 1: Trans-thoracic Echocardiography showing severe right ventricular (RV) enlargement and high pulmonary artery pressure (PASP:
45 mmHg).
Figure1. 2: Left: Chest computed tomography (CT) image showing a wedge consolidation in left lower lobe of lung, Right: Chest CT Angiog-
raphy demonstrating large filling defect in main pulmonary artery and both main bronchi
and moderate RV dysfunction with moderate tricuspid re-
gurgitation and elevated pulmonary artery systolic pressure
(pulmonary artery systolic pressure (PASP): 45 mmHg).
A chest computed tomography (CT) scan showed a wedge
consolidation in left lower lobe of lung (Figure 1.2 left). Ac-
cording to the above findings, PE was diagnosed for the pa-
tients and chest CT angiography was done, which demon-
strated a large filling defect in main pulmonary artery and
both main bronchi (Figure 1.2 right).
Considering clinical presentation, unstable hemodynamics,
and pulmonary CT angiography findings, massive PE was di-
agnosed. Hypotension didn’t correct with fluid resuscitation
and vasopressor therapy. Hypoxemia and tachycardia per-
sisted and the patient was lethargic. In brain CT scan, hemor-
rhagic transformation in territory of prior CVA was reported
(Figure 1.3 left). Fibrinolytic therapy was contraindicated
due to history of CVA 20 days before and surgery or embolec-
tomy by catheter were choice treatments but they were not
available and transferring him to another hospital was not
possible.
Considering patient’s critical situation and the risk of devel-
oping intracranial hemorrhage, Alteplase was administered
with dose (50 mg during 2 hours) then heparin infusion was
started after normalization of PTT (after 4 hours). Within 2
hours of thrombolysis, level of consciousness, hypotension,
and hypoxemia improved (Saturation O2 = 95% and BP =
120/85 mmHg).
The findings of repeated trans-thoracic echocardiography
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Figure1. 3: Brain CT scan before (Left) and after (Right) fibrinolysis showing hemorrhagic transformation in territory of prior CVA without
change.
Figure1. 4: CT angiography after treatment showing reduction of
thrombus bulk and RV size
showed significant improvement in RV size and RV function.
PASP had dropped to 28 mmHg. Pulmonary CT angiography
was done 24 hours after treatment and showed reduction of
thrombus bulk and RV size (Figure 1.4).
Two control brain CT scans (4 h and 24 h after treatment)
didn’t show any new intracranial hemorrhage (figure 1.3
right). The patient was discharged from the hospital after 5
days with prescription of Rivaroxaban 15 mg twice a day and
he was in a good condition.
Case 2
A 52-year-old man was admitted to our emergency depart-
ment with complaint of syncope. The patient also com-
plained of dyspnea. He had a history of recent surgery for
cervical discopathy 18 days before.
His vital signs upon arrival to the emergency department
showed a systolic blood pressure of 65 mmHg, a heart rate
of 118 beats per minute, a respiratory rate of 28 per minute
& oxygen saturation of 80% in ambient air. In physical ex-
amination, jugular veins were distended and cardiac exam
showed tachycardia and a right ventricular heave. Pul-
monary examination was unremarkable.
The initial electrocardiogram showed sinus tachycardia at a
rate of 118 per minute, S1Q3T3 pattern and inverted T wave
in V1-V3.
Bedside echocardiography showed severe RV dilation, mod-
erate RV dysfunction, moderate tricuspid regurgitation, el-
evated pulmonary artery pressure (PAP: 60 mmHg), Mc-
Connell sign with no RV and RA clot. CT angiography of pul-
monary arteries was performed due to suspicion of PE. The
findings of CT angiography (figure 2.1) confirmed Saddle em-
bolism in pulmonary arteries (filling defects in main, left and
right pulmonary artery).
According to the above findings, massive PE was diagnosed
but the patient had absolute contraindication for fibrinolytic
therapy due to recent spinal surgery, so he became candidate
for emergent surgery or embolectomy by catheter but this
procedure was not available and critical condition of patient
did not allow us to transfer him to another hospital. So we
decided to administrate fibrinolytic. Alteplase was adminis-
trated with a dose of 100 mg for 2 hours.
The patient felt much better and blood pressure rose after
termination of Alteplase infusion. Repeated bedside trans-
thoracic echocardiography showed reduction in RV size and
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Figure2. 1: Pulmonary computed tomography angiography confirmed Saddle embolism in pulmonary arteries.
Figure3. 1: Electrocardiogram shows sinus tachycardia and right bundle branch block.
pulmonary artery pressure. During the hospital stay, the pa-
tient was continuously monitored for bleeding of the site of
surgery, and no complication was observed. So, on the sixth
day, he was discharged with a good general condition.
Case 3
A 48 Year-old female, with a known case of brain tumor, pre-
sented to our emergency department complaining of dysp-
nea and drowsiness since 4 days before. She had history of
emergency department admission 4 weeks before following
headache and loss of consciousness and diagnosis of brain
tumor with right parietal lobe involvement and intratumoral
hemorrhage. She underwent mass resection and was dis-
charged from the hospital after 8 days of hospitalization. 24
days after discharge she presented to emergency department
with complaint of severe shortness of breath.
Her vital signs upon arrival to the emergency department
showed a systolic blood pressure of 60 mmHg, a heart rate
of 145 beats per minute, an oral temperature of 38◦C, a respi-
ratory rate of 35 per minute, and oxygen saturation of 50% in
ambient air.
Initially, due to hypotension, fever and cold limbs were di-
agnosed with septic shock-induced meningitis or pneumo-
nia treated with broad-spectrum antibiotics and vasopressor.
The initial electrocardiogram showed sinus tachycardia at a
rate of 135 per minute, right bundle branch block with a QRS
duration of 125 milliseconds and right axis deviation of 120
degrees (figure 3.1).
Both lower extremities swelling developed and subsequent
compression ultrasound and Doppler studies revealed bilat-
eral acute extensive thrombus formation in the deep veins
to the level of iliac. Pulmonary CT angiography confirmed
large bilateral pulmonary thromboembolic (saddle-shaped
embolism with obstruction of 85% of the arterial substrate)
with radiological evidence of RV strain (figure 3.2).
Fibrinolytic therapy was contraindicated due to history of
brain tumor and recent surgery 28 days before and surgery
or embolectomy by catheter were choice treatments but
the patient’s clinical condition was not suitable for surgery
and transferring her to another hospital for embolectomy by
catheter was not possible. Ultimately despite absolute con-
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Figure3. 2: Pulmonary CT angiography demonstrates bilateral pulmonary thromboembolism with RV dilatation.
Figure3. 3: Electrocardiogram shows normal sinus tachycardia.
traindications, Alteplase was administered with dose (25 mg during 1 hours). Approximately 24 hour after termination
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of thrombolytic therapy, blood pressure returned to115/75
mmHg, with a heart rate of 90 beats per minute and a respi-
ratory rate of 20 per minute with an oxygen saturation of 88%
in ambient air. Electrocardiogram then showed sinus tachy-
cardia at a rate of 125 per minute, normal QRS duration and
normal axis (Figure 3.3).
Control brain CT scans didn’t show any new intracranial
hemorrhage (48h after treatment). After 72 hours, patient’s
level of consciousness returned to the previous level and the
patient was discharged on the seventh day with oral admin-
istration of rivaroxaban.
3. Discussion
American Heart Association (AHA) (11) and ACCP Guidelines
(12) advise advanced treatments such as systemic fibrinolysis
through a peripheral vein, pharmaco-mechanical catheter–
directed therapy and surgical embolectomy for patients with
massive PE.
Patients being considered for systemic fibrinolysis have to be
screened for contraindication. The overall risk of intracranial
hemorrhage in patients who receive fibrinolysis is relatively
low (0.9%) (13), but studies have shown that the use of fib-
rinolysis has decreased by 50% in patients with massive PE
over the last decade due to fear of intracranial hemorrhage
(14).
Physicians when faced with patients with massive PE that
concomitantly have contraindication for fibrinolysis, have to
choose other treatments due to fear of complications, espe-
cially intracranial hemorrhage.
Unfortunately, other therapeutic options, such as pharmaco-
mechanical catheter–directed therapy and surgical embolec-
tomy are not available in all hospitals or, if available, may be
rejected by surgeons or anesthesiologists because of the high
risk of intervention.
In this case series, we presented three cases, in which diag-
nosis of massive PE was affirmed based on clinical presen-
tations and images. All cases had contraindication for fibri-
nolytic therapy.
Due to the inability to use other treatments and patients’
critical condition, as non-treatment leads to death of pa-
tients, we had to administrate fibrinolysis. Despite the risk of
bleeding, fortunately, there were no fibrinolytic side effects
in these patients. All cases had dramatic responses to fibri-
nolytic administration. They were discharged from the hos-
pital with a good general condition.
4. Conclusion:
In some critical conditions, physicians are confronted with
the question: how can I manage massive PE in the presence
of absolute contraindication for fibrinolytic? It seems that,
if no other acceptable treatments are available, physicians
could consider fibrinolytic therapy to save the patient’s life.
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